Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma - PubMed (original) (raw)
Review
doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
F Stephen Hodi, Jeffrey S Weber, James P Allison, Walter J Urba, Caroline Robert, Steven J O'Day, Axel Hoos, Rachel Humphrey, David M Berman, Nils Lonberg, Alan J Korman
Affiliations
- PMID: 23772560
- PMCID: PMC3910157
- DOI: 10.1111/nyas.12180
Free PMC article
Review
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D Wolchok et al. Ann N Y Acad Sci. 2013 Jul.
Free PMC article
Abstract
The immunotherapeutic agent ipilimumab has helped address a significant unmet need in the treatment of advanced melanoma. Ipilimumab is a fully human monoclonal antibody that targets cytotoxic T-lymphocyte antigen-4 (CTLA-4), thereby augmenting antitumor immune responses. After decades in which a number of clinical trials were conducted, ipilimumab was the first therapy to improve overall survival in a randomized, controlled phase III trial of patients with advanced melanoma. These results led to the regulatory approval of ipilimumab at 3 mg/kg for the treatment of unresectable or metastatic melanoma. More than 17,000 patients worldwide have received ipilimumab, either as a commercial drug at 3 mg/kg or in clinical trials and expanded access programs at different doses. Consistent with its proposed mechanism of action, the most common toxicities associated with ipilimumab therapy are inflammatory in nature. These immune-related adverse events were mostly reversible when effective treatment guidelines were followed. Importantly, long-term follow-up of patients who received ipilimumab in a phase III trial showed that 24% survived at least two years, and in phase II studies, a proportion of patients survived at least five years. Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers.
Keywords: cytotoxic T-lymphocyte antigen-4; immuno-oncology; immunotherapy; ipilimumab; melanoma; monoclonal antibody.
© 2013 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.
Figures
Figure 1
Key milestones in the development of ipilimumab. Following preclinical studies of CTLA-4 blockade in murine tumor models, ipilimumab was developed as a fully human monoclonal antibody and evaluated in several clinical trials. These trials included two randomized, controlled phase III trials in which ipilimumab demonstrated an improvement in OS. Ipilimumab received approval in 2011 in both the United States and the European Union for the treatment of patients with unresectable or metastatic melanoma. Ongoing evaluation of ipilimumab includes combination studies with other anticancer therapies (e.g., RT, anti-PD-1 antibody), as an adjuvant therapy for stage III melanoma, and its efficacy and safety in several other solid tumors.
Figure 2
Mechanism of action of ipilimumab. Competitive inhibition of CD28-B7.1/B7.2 binding by CTLA-4 suppresses T cell activation and prevents an immune response. Blockade of CTLA-4 with ipilimumab allows continued T cell activation to augment the antitumor response. Other regulatory checkpoints with the potential for modulation include the coinhibitory molecule PD-1 as well as costimulatory molecules OX40 and 4-1BB.
Figure 3
Kaplan–Meier analysis of overall survival in the phase III study MDX010-20. Separation of the Kaplan–Meier survival curves was not observed until three months, at which time an OS benefit of approximately four months was observed with ipilimumab treatment compared with the gp100 control. Survival in the ipilimumab monotherapy group reached a plateau after two years, indicating durable response and long-term survival benefits. The table shows data for the primary endpoint of OS, and secondary endpoints of 1- and 2-year survival rates. Modified, with permission, from Ref. .
Figure 4
Kaplan–Meier analysis of overall survival in the phase III study CA184-024. Survival analysis of OS in treatment-naive patients with advanced melanoma who received ipilimumab at 10 mg/kg plus DTIC or placebo plus DTIC in the phase III trial, CA184-024. The survival curves reach a plateau beginning at approximately three years after initiation of treatment. Continued survival follow-up of more than four years demonstrates a long-term survival benefit that is consistent with the results of other ipilimumab studies. The table shows data for the primary endpoint of OS, with secondary endpoints of 1-, 2-, and 3-year survival rates as originally reported and 4-year survival rates based on recent survival follow-up.
Similar articles
- The ipilimumab lesson in melanoma: achieving long-term survival.
Delyon J, Maio M, Lebbé C. Delyon J, et al. Semin Oncol. 2015 Jun;42(3):387-401. doi: 10.1053/j.seminoncol.2015.02.005. Epub 2015 Feb 17. Semin Oncol. 2015. PMID: 25965357 Review. - Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G, Tentori L, Navarra P. Graziani G, et al. Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review. - Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Hoos A, et al. Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Semin Oncol. 2010. PMID: 21074069 Review. - Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C, Khushalani NI, Zager JS. Luu C, et al. Expert Opin Biol Ther. 2016 Dec;16(12):1491-1499. doi: 10.1080/14712598.2016.1233961. Epub 2016 Sep 20. Expert Opin Biol Ther. 2016. PMID: 27602429 Review. - Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP, Woodman SE. Patel SP, et al. Drug Des Devel Ther. 2011;5:489-95. doi: 10.2147/DDDT.S10945. Epub 2011 Dec 16. Drug Des Devel Ther. 2011. PMID: 22267918 Free PMC article. Review.
Cited by
- Long-Term Survival in Patients With Advanced Melanoma.
van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot J W B JW, Hospers GAP, Kapiteijn E, Leeneman B, D P, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. van Not OJ, et al. JAMA Netw Open. 2024 Aug 1;7(8):e2426641. doi: 10.1001/jamanetworkopen.2024.26641. JAMA Netw Open. 2024. PMID: 39141388 Free PMC article. - Immune Cytolytic Activity and Strategies for Therapeutic Treatment.
Agioti S, Zaravinos A. Agioti S, et al. Int J Mol Sci. 2024 Mar 23;25(7):3624. doi: 10.3390/ijms25073624. Int J Mol Sci. 2024. PMID: 38612436 Free PMC article. Review. - Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38370537 Free PMC article. - Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A, Daud AI. Haugh A, et al. Am J Clin Dermatol. 2024 May;25(3):407-419. doi: 10.1007/s40257-023-00841-0. Epub 2024 Feb 8. Am J Clin Dermatol. 2024. PMID: 38329690 Review. - XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, McLaughlin M, Moore-Lai D, O'Toole C, Liu Z, Nicholson B, Flesch V, Qiu H, Clackson T, O'Hagan RC, Rodeck U, Karow M, O'Neil J, Williams JC. Jenkins KA, et al. J Immunother Cancer. 2023 Dec 12;11(12):e007785. doi: 10.1136/jitc-2023-007785. J Immunother Cancer. 2023. PMID: 38164757 Free PMC article.
References
- American Cancer Society. Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume....
- Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010;60::277–300. - PubMed
- Korn EL, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 2008;26::527–534. - PubMed
- Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastases: a literature review. Cancer Control. 2009;16::248–255. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical